Understanding the Market | TRANSTHERA-B rises over 18% again, total market value surpasses HKD 50 billion, and the Phase II trial of Entrectinib for breast cancer is approved
I'm PortAI, I can summarize articles.
TRANSTHERA-B's stock price rose over 18% again, reaching a new high of HKD 129.3, with a total market value exceeding HKD 50 billion. The current stock price is HKD 125, with a trading volume of HKD 151 million. The company's core product, Tengrutini, has received approval from the National Medical Products Administration of China for its Phase II clinical trial targeting recurrent or metastatic breast cancer, demonstrating unique therapeutic value and gaining recognition from regulatory agencies in multiple countries
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments